Senators blast HHS’ restrictive coverage for Alzheimer’s drugs
Mar 24, 2023
Health and Human Services Secretary Xavier Becerra came under fire Wednesday during a Senate Finance Committee meeting regarding the Centers for Medicare & Medicaid Services’ restrictive national...
Clinical briefs for Thursday, March 23
Mar 23, 2023
Rural nursing home residents reap benefits from mental healthcare through video … NIH: Prior COVID-19 infection dampens response to vaccination … Skirting cholesterol targets raises CV events by 44...
Readmission rates, episode costs higher for patients with dementia
Mar 20, 2023
The cost of 30-day readmission and total 30-day episode costs are higher for patients with Alzheimer disease and related dementias, researchers report.
Alzheimer’s Association lobbies to expand coverage for new drugs
Mar 20, 2023
The Alzheimer’s Association is lobbying lawmakers to convince the Biden administration to reconsider a decision not to provide full coverage for new Alzheimer’s drugs which the organization believes...
Clinicians missing ‘critical’ step in Alzheimer’s diagnoses, 2023 report finds
Mar 16, 2023
Clinicians are not proactive in engaging patients on the subject of memory concerns, missing a key chance for timely diagnosis and early treatment, finds an Alzheimer’s Association report released...
Patient advocates decry CMS decision on Alzheimer’s drug coverage
Feb 24, 2023
The Alzheimer’s Association and others have strongly criticized a decision by CMS to stand by its highly restrictive coverage for new dementia drugs.
Antipsychotic meds decisions in assisted living require system-level perspective: study
Jan 25, 2023
Decisions on administering as-needed antipsychotic drugs require balancing regulatory goals with resident-centered practices, researchers say.
FDA denies request for expedited approval of Alzheimer’s drug
Jan 23, 2023
The Food and Drug Administration late last week denied Ely Lilly’s request for expedited approval of the Alzheimer’s drug donanemab, citing the need for more clinical trials to test the safety and...
Also in the News for Tuesday, Jan. 10
Jan 10, 2023
Share of adults with long COVID symptoms declining … FDA approves new drug Leqembi to treat early Alzheimer’s disease … 1 in 4 adults with chronic pain trying cannabis for relief
BREAKING: FDA approves new experimental drug to treat early Alzheimer’s
Jan 06, 2023
The Food and Drug Administration has approved the experimental Alzheimer’s drug Leqembi (lecanemab-irmb) for clinical use in patients with early disease.